Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recollections from an extraordinary 19-year journey guiding a tiny startup with an unproven therapeutic modality into a mature drug company with marketed products and >1,600 employees in nearly 20 countries provide lessons for those seeking to create the culture and values that are core to biotech success.
Commercializing research is fraught with pitfalls, but a thoughtful checklist can ensure you set off on the right path and give your fledgling business the best chance of success.
A historical analysis of oncology deals can help bioentrepreneurs navigate the right time for partnerships and exits and can inform on the type of investors likely to be interested.
Ask any pharma executive whether their company is interested in academic collaborations and the answer is a resounding “yes.” So why do so few academic institutions have success stories to share?
A detailed look at the economic impact of university-licensed life science startups across the United States reveals vast differences in the effectiveness of different regions to create ventures and sustain them as viable entities.
Traditional valuation approaches rarely take into account scientific considerations specific to a R&D project. A question-based approach using real options offers a solution.
A deep dive into the influence of research output, patenting, venture capital and human capital on startup financing activity in Europe reveals not all countries are equal.
